ClinicalTrials.gg
CompletedNCT00847626Updated Feb 7, 2012Results posted

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Hypertension, sponsored by Takeda. Completed at 99 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-07.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,711
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
Largest of 21
1,711 · median 566
Started
2009
with 3 others
Phase 3
17 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one has the largest enrollment, is one of 4 that started in 2009, is one of 17 in phase 3, and was the 13th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.

Read the detailed description

According to the World Health Organization (WHO), hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully.

Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker that is being evaluated by Takeda to treat essential hypertension.

Treatments for essential hypertension commonly include use of a thiazide-like diuretic, either alone or as part of combination treatment.

This study is designed to compare the antihypertensive effect and the safety and tolerability of the azilsartan medoxomil plus chlorthalidone fixed-dose combination product (TAK 491CLD FDC) with azilsartan monotherapy and chlorthalidone monotherapy during 8 weeks of treatment.

Participants in this study will be randomized to receive one of 11 possible dosing combinations of azilsartan medoxomil , chlorthalidone and placebo over an 8 week period. The total duration of the study will be approximately 13 weeks. Participants will make 12 visits to the clinic. Each participant will also be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Hypertension

Keywords

  • Hypertensive
  • Blood Pressure, High
  • Vascular Disease
  • Cardiovascular Disease
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg on the day prior to randomization, or the participant has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg at the Screening Visit and on the day prior to randomization.
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be .
  4. Is willing to discontinue current antihypertensive medications on Day -21 or on Day -28 if on amlodipine or chlorthalidone.

Exclusion criteria

Exclusion Criteria:

  1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg on the day prior to randomization.
  2. Has a baseline 24-hour ambulatory blood pressure measurement reading of insufficient quality.
  3. Has works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]).
  4. Has an upper arm circumference less than 24 cm or greater than 42 cm.
  5. Has is noncompliant with study medication during the placebo run-in period.
  6. Has secondary hypertension of any etiology.
  7. Has recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  8. Has cardiac conduction defects.
  9. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  10. Has severe renal dysfunction or disease.
  11. Has known or suspected unilateral or bilateral renal artery stenosis.
  12. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
  13. Has poorly controlled type 1 or type 2 diabetes mellitus at Screening.
  14. Has hypokalemia or hyperkalemia.
  15. Has an or aspartate aminotransferase level of greater than 2.5 times the , active liver disease, or jaundice.
  16. Has any other known serious disease or condition that would compromise safety, might affect , or make it difficult to successfully manage and follow Has according to the protocol.
  17. Has known to angiotensin II receptor blockers, thiazide-type diuretics or other sulfonamide-derived compounds.
  18. Has been randomized in a previous azilsartan medoxomil study.
  19. Is currently participating in another study or is receiving or has received any investigational compound within 30 days prior to Screening.
  20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,711 participants (actual)

Study arms

  • Experimental
    Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Active comparator
    Chlorthalidone 12.5 mg QD

    Drug: Chlorthalidone

  • Active comparator
    Chlorthalidone 25 mg QD

    Drug: Chlorthalidone

  • Experimental
    Azilsartan medoxomil 20 mg QD

    Drug: Azilsartan medoxomil

  • Experimental
    Azilsartan medoxomil 40 mg QD

    Drug: Azilsartan medoxomil

  • Experimental
    Azilsartan medoxomil 80 mg QD

    Drug: Azilsartan medoxomil

Interventions

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

  • Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

    Also known as: TAK-491CLD

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)

    The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8.

  2. Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)

    The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8.

Secondary outcomes

  1. Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

    The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 8

  2. Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)

    The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8.

  3. Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)

    The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8.

  4. Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

    The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 8.

  5. Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8.

  6. Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8.

  7. Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8.

  8. Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8.

  9. Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8.

  10. Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8.

  11. Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8.

  12. Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 8

  13. Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 8.

  14. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.

    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.

    Time frame: Baseline and Week 8

  15. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.

    Time frame: Baseline and Week 8.

  16. Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.

    Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.

    Time frame: Baseline and Week 8.

07

Results

Posted Feb 7, 2012

Participant flow

Participants enrolled at 175 investigative sites in Austria, Chile, Germany, Guatemala, Mexico, Netherlands, Peru, Poland, Russian Federation and the United States from 29 January 2009 to 10 July 2010.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Started156154147156153162157160155153162
Completed135131131125125125135141141139142
Not completed2123163128372219141420
Withdrew: Adverse event1010619112246366
Withdrew: Protocol violation21211111011
Withdrew: Lost to follow-up01110313101
Withdrew: Withdrawal by subject553812984452
Withdrew: Lack of efficacy31012062517
Withdrew: Other15412223113

Outcome measures

PrimaryChange From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)

The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)
mmHgAzilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)-28.9 ± 0.89-15.9 ± 1.16-15.1 ± 1.19
Statistical analysis
  • Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (net): -13.0 · 95% CI -15.8 to -9.5
  • Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -13.8 · 95% CI -16.7 to -10.9
SecondaryChange From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure-33.8 ± 1.26-37.0 ± 1.26-36.8 ± 1.30-39.5 ± 1.25-36.9 ± 1.27-40.1 ± 1.24-21.1 ± 1.25-27.1 ± 1.25-19.8 ± 1.26-23.3 ± 1.27-24.2 ± 1.23
Statistical analysis
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD vs Chlorthalidone 12.5 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -12.7 · 95% CI -16.2 to -9.2
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -9.9 · 95% CI -13.4 to -6.4
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD vs Chlorthalidone 12.5 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -15.7 · 95% CI -19.2 to -12.1
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -12.4 · 95% CI -15.8 to -8.9
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD vs Chlorthalidone 12.5 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -15.8 · 95% CI -19.3 to -12.3
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -13.0 · 95% CI -16.5 to -9.5
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 20 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -14.0 · 95% CI -17.5 to -10.5
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 20 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -17.2 · 95% CI -20.6 to -13.7
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 40 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -13.5 · 95% CI -17.0 to -9.9
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 40 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -16.2 · 95% CI -19.7 to -12.7
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -12.8 · 95% CI -16.3 to -9.3
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -16.0 · 95% CI -19.4 to -12.6
SecondaryChange From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)

The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)
mmHgAzilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)-28.2 ± 2.49-23.4 ± 3.36-9.9 ± 2.97
Statistical analysis
  • Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = 0.255 (Tested at 5% significance level.) · Mean difference (final values): -4.8 · 95% CI -13.0 to 3.5
  • Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -18.2 · 95% CI -25.9 to -10.6
SecondaryChange From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)

The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)-27.2 ± 3.21-25.4 ± 3.36-21.5 ± 3.21-31.9 ± 3.61-24.8 ± 3.71-24.4 ± 3.43-12.2 ± 3.22-23.4 ± 3.36-10.7 ± 3.10-11.0 ± 3.04-9.9 ± 2.97
SecondaryChange From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure-14.4 ± 0.72-15.5 ± 0.72-15.6 ± 0.74-17.0 ± 0.72-16.9 ± 0.73-18.5 ± 0.71-7.4 ± 0.72-9.2 ± 0.72-6.7 ± 0.72-9.2 ± 0.73-9.9 ± 0.70
SecondaryChange From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.

The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.-13.3 ± 0.80-15.0 ± 0.83-13.5 ± 0.83-17.3 ± 0.85-16.5 ± 0.86-16.1 ± 0.85-6.5 ± 0.79-7.5 ± 0.78-7.9 ± 0.80-7.3 ± 0.79-8.9 ± 0.80
SecondaryChange From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring-24.0 ± 0.97-26.7 ± 1.01-26.1 ± 1.01-30.4 ± 1.03-27.9 ± 1.04-28.1 ± 1.03-10.9 ± 0.96-14.7 ± 0.95-11.7 ± 0.97-12.6 ± 0.96-15.3 ± 0.97
SecondaryChange From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring-13.5 ± 0.60-15.0 ± 0.62-14.9 ± 0.63-17.3 ± 0.64-16.5 ± 0.65-15.9 ± 0.64-5.6 ± 0.59-6.7 ± 0.59-6.8 ± 0.60-7.6 ± 0.59-8.8 ± 0.60
SecondaryChange From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.-24.4 ± 1.01-27.7 ± 1.05-26.7 ± 1.06-31.2 ± 1.07-28.4 ± 1.09-28.5 ± 1.07-10.8 ± 1.00-14.7 ± 0.99-11.7 ± 1.01-12.8 ± 1.00-15.7 ± 1.01
SecondaryChange From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.-13.7 ± 0.64-15.6 ± 0.66-15.1 ± 0.66-17.6 ± 0.67-16.8 ± 0.69-16.2 ± 0.67-5.6 ± 0.63-6.5 ± 0.62-6.8 ± 0.64-7.7 ± 0.63-9.1 ± 0.64
SecondaryChange From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.-22.5 ± 1.09-24.0 ± 1.13-24.3 ± 1.14-28.1 ± 1.15-26.5 ± 1.17-26.3 ± 1.15-11.3 ± 1.08-14.4 ± 1.06-11.8 ± 1.09-11.8 ± 1.08-14.2 ± 1.09
SecondaryChange From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.-12.8 ± 0.71-13.5 ± 0.73-14.4 ± 0.74-16.2 ± 0.75-15.8 ± 0.76-14.9 ± 0.75-6.0 ± 0.70-7.1 ± 0.69-6.9 ± 0.70-7.5 ± 0.69-8.0 ± 0.71
SecondaryChange From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.-24.6 ± 1.07-28.0 ± 1.11-27.1 ± 1.12-31.7 ± 1.13-28.5 ± 1.15-28.7 ± 1.13-10.4 ± 1.06-14.5 ± 1.04-11.8 ± 1.07-12.7 ± 1.05-15.8 ± 1.07
SecondaryChange From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.-13.6 ± 0.68-15.6 ± 0.71-15.4 ± 0.71-17.8 ± 0.72-16.8 ± 0.73-16.2 ± 0.72-5.3 ± 0.67-6.3 ± 0.66-6.8 ± 0.68-7.6 ± 0.67-9.2 ± 0.68
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.
percentage of participantsAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.86.488.990.393.586.894.956.176.953.564.566.7
PrimaryChange From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)

The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)
mmHgAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)-22.9 ± 1.19-26.3 ± 1.24-24.4 ± 1.24-29.8 ± 1.26-26.3 ± 1.28-28.0 ± 1.26-12.7 ± 1.18-15.9 ± 1.16-12.1 ± 1.19-12.8 ± 1.17-15.1 ± 1.19
Statistical analysis
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD vs Chlorthalidone 12.5 mg QD · ANCOVA · p = < 0.001 (Tested at 5% significance level.) · Mean difference (final values): -10.3 · 95% CI -13.6 to -7.0
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -10.4 · 95% CI -13.7 to -7.0
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD vs Chlorthalidone 12.5 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -11.8 · 95% CI -15.1 to -8.4
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -13.9 · 95% CI -17.3 to -10.6
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD vs Chlorthalidone 12.5 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -13.7 · 95% CI -17.1 to -10.3
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -12.0 · 95% CI -15.4 to -8.7
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 20 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -10.9 · 95% CI -14.2 to -7.6
  • Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 20 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -14.2 · 95% CI -17.6 to -10.9
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 40 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -11.6 · 95% CI -15.0 to -8.3
  • Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 40 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -17.0 · 95% CI -20.4 to -13.6
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -11.2 · 95% CI -14.7 to -7.8
  • Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = <0.001 (Tested at 5% significance level.) · Mean difference (final values): -12.8 · 95% CI -16.2 to -9.4
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.
percentage of participantsAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.89.689.587.694.890.196.863.978.860.671.174.7
SecondaryPercentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.

Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.
percentage of participantsAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.83.184.384.891.082.893.045.867.939.455.362.3

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started on or after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD—3/156 (1.9%)52/156 (33.3%)
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD—0/154 (0%)55/154 (35.7%)
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD—1/146 (0.7%)40/146 (27.4%)
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD—2/156 (1.3%)74/156 (47.4%)
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD—2/153 (1.3%)52/153 (34%)
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD—2/161 (1.2%)67/161 (41.6%)
Chlorthalidone 12.5 mg QD—0/156 (0%)51/156 (32.7%)
Chlorthalidone 25 mg QD—2/160 (1.3%)53/160 (33.1%)
Azilsartan Medoxomil 20 mg QD—2/155 (1.3%)25/155 (16.1%)
Azilsartan Medoxomil 40 mg QD—2/153 (1.3%)36/153 (23.5%)
Azilsartan Medoxomil 80 mg QD—3/162 (1.9%)32/162 (19.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Metabolic encephalopathyNervous system disorders0/1560/1541/1460/1560/1530/1610/1560/1600/1550/1530/162
Myocardial ischaemiaCardiac disorders0/1560/1540/1460/1560/1530/1610/1560/1601/1551/1530/162
Supraventricular tachycardiaCardiac disorders0/1560/1540/1460/1560/1530/1610/1560/1600/1551/1530/162
Non-cardiac chest painGastrointestinal disorders0/1560/1540/1460/1560/1530/1610/1560/1600/1551/1530/162
Blood urea increasedInvestigations1/1560/1540/1460/1561/1530/1610/1560/1600/1550/1530/162
Blood creatinine increasedInvestigations0/1560/1540/1460/1561/1530/1610/1560/1600/1550/1530/162
Blood uric acid increasedInvestigations0/1560/1540/1460/1561/1530/1610/1560/1600/1550/1530/162
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1560/1540/1460/1561/1530/1610/1560/1600/1550/1530/162
Bipolar disorderPsychiatric disorders0/1560/1540/1460/1560/1530/1610/1560/1601/1550/1530/162
Suicidal ideationPsychiatric disorders0/1560/1540/1460/1560/1530/1610/1560/1601/1550/1530/162
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Blood creatinine increasedInvestigations15/15619/15417/14629/15618/15332/1615/1569/1604/1555/1536/162
DizzinessNervous system disorders12/15617/15420/14621/15619/15319/1616/1565/1602/1557/1536/162
HeadacheNervous system disorders8/15612/1541/1469/15611/15311/16119/15617/16013/15511/15312/162
HypokalaemiaMetabolism and nutrition disorders3/1562/1540/1465/1560/1532/1614/15619/1600/1551/1530/162
Blood creatine phosphokinase increasedInvestigations3/1564/1543/14610/1563/1533/1616/1567/1606/1557/1536/162
HyperuricaemiaMetabolism and nutrition disorders2/1566/1544/1463/1563/15310/1613/1563/1600/1550/1530/162
Blood uric acid increasedInvestigations3/1569/1546/1467/1569/1533/1616/1565/1601/1552/1531/162
Blood urea increasedInvestigations1/1566/1544/1468/1566/1539/1610/1564/1600/1550/1531/162
NasopharyngitisInfections and infestations8/1565/1542/1467/1562/1533/1616/1564/1602/1557/1532/162
Muscle spasmsMusculoskeletal and connective tissue disorders8/1562/1540/1466/1562/1534/1612/1560/1602/1550/1532/162

Baseline characteristics

Age Continuous
Age Continuous(years)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Mean58.2 ± 10.5757.4 ± 11.1356.2 ± 10.5057.4 ± 11.0755.8 ± 11.2257.6 ± 11.0457.3 ± 11.3056.2 ± 10.0457.3 ± 11.0457.8 ± 10.2857.3 ± 10.8757.2 ± 10.82
Age, Customized
Age, Customized(participants)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
<45 years1516172125192118181716203
Between 45 to 64 years989710093901049710897981071089
≥65 years4341304238393933403839422
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Female86777685821007490876884909
Male7077717171628369688578805
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Hispanic or Latino1019111519151719201715177
Not Hispanic or Latino9075768571878486778086897
Unknown or Not Reported5660605663605654585661640
Race (NIH/OMB)
Race (NIH/OMB)(participants)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
American Indian or Alaska Native913131312161414111314142
Asian4344231711434
Native Hawaiian or Other Pacific Islander010000100002
Black or African American3428293026343129313535342
White1111121021111141091111111131051111210
More than one race2212101211215
Unknown or Not Reported000000000000
Region of Enrollment
Region of Enrollment(participants)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Austria100010000002
Chile3332232123226
Germany4665654534553
Guatemala889101088989996
Mexico10111191211118131112119
Netherlands6765756666767
Peru1112131212141211131212134
Poland8878887887885
Russian Federation5555566654658
United States10094871009010210110597971011074
Height
Height(cm)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Mean166.3 ± 11.71166.6 ± 10.85167.1 ± 11.44166.8 ± 11.64166.6 ± 10.81165.4 ± 10.79168.3 ± 11.07166.1 ± 11.36166.4 ± 10.65167.7 ± 12.27167.1 ± 11.85166.8 ± 11.32
Weight
Weight(kg)Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QDAzilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QDChlorthalidone 12.5 mg QDChlorthalidone 25 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Mean89.85 ± 22.07686.06 ± 18.05689.28 ± 21.48490.16 ± 21.94987.31 ± 19.20986.44 ± 20.41289.12 ± 21.04986.70 ± 20.27087.27 ± 18.93487.54 ± 19.01986.27 ± 20.35487.80 ± 20.289

3 further baseline measures are reported on the registry.

08

Study locations

99 sites
  • Birmingham, Alabama, United States
  • Columbiana, Alabama, United States
  • Tuscaloosa, Alabama, United States
  • Chandler, Arizona, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Buena Park, California, United States
  • Carmichael, California, United States
  • Costa Mesa, California, United States
  • Irvine, California, United States
  • Palm Springs, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Vista, California, United States
  • Walnut Creek, California, United States
  • Middletown, Delaware, United States
  • Bradenton, Florida, United States
  • Deerfield Beach, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Hallandale Beach, Florida, United States
  • Hialeah, Florida, United States
  • Jacksonville, Florida, United States
  • Longwood, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Ormond Beach, Florida, United States
  • St Petersburg, Florida, United States
  • Atlanta, Georgia, United States
  • Buffalo Grove, Illinois, United States
  • Libertyville, Illinois, United States
  • Melrose Park, Illinois, United States
  • Fishers, Indiana, United States
  • Indianapolis, Indiana, United States
  • Erlanger, Kentucky, United States
  • Madisonville, Kentucky, United States
  • Paducah, Kentucky, United States
  • Rockville, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Chesterfield, Michigan, United States
  • St Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Henderson, Nevada, United States
  • Brick, New Jersey, United States
  • Margate, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Endwell, New York, United States
  • Cary, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Dayton, Ohio, United States
  • Lyndhurst, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Ashland, Oregon, United States
  • Altoona, Pennsylvania, United States
  • Bensalem, Pennsylvania, United States
  • Feasterville, Pennsylvania, United States
  • Jenkintown, Pennsylvania, United States
  • Sellersville, Pennsylvania, United States
  • Warminster, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Florence, South Carolina, United States
  • Murrells Inlet, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Spartanburg, South Carolina, United States
  • Clarksville, Tennessee, United States
  • New Tazewell, Tennessee, United States
  • Austin, Texas, United States
  • Bellaire, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • McKinney, Texas, United States
  • Richardson, Texas, United States
  • San Antonio, Texas, United States
  • Magna, Utah, United States
  • West Jordan, Utah, United States
  • Arlington, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Oregon, Wisconsin, United States
  • Santiago, Chile
  • Temuco, Chile
  • Aguascalientes, Mexico
  • Merida, Mexico
  • Mexico DF, Mexico
  • Bellavista, Peru
  • Chiclayo, Peru
  • Jesus Maria, Peru
  • Miraflores, Peru
  • San Borja, Peru
  • San Martin de Porres, Peru
  • Trujillo, Peru
  • Umacollo, Peru
  • Moscow, Russian Federation
  • St. Petersburg, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of May 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2009
First posted
Feb 19, 2009
Start
Jan 2009
Primary completionActual
May 2010
CompletionActual
Jul 2010
Results first posted
Feb 7, 2012
Last update
Feb 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00847626
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 19, 2009
Start date
Jan 2009
Primary completion
May 2010
Completion
Jul 2010
Results posted
Feb 7, 2012
Last update
Feb 7, 2012

Study contacts

Executive Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone

Start the discussion